ARQT News and Press, Arcutis Biotherapeutics Inc. From 12/15/23

2023-12-15 08:46:33 ET Aurora Technology Acquisition  ( ATAK ) +50% . Brilliant Acquisition  ( BRLI ) +27% . Ikena Oncology ( IKNA ) +24% . SportsMap Tech Acquisition  ( SMAP ) +14% . Pineapple Financial  ( PAPL ) +1%...

2023-11-29 15:09:18 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...

FDA has set a PDUFA target action date of July 07, 2024 Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United States sNDA supported by positive efficacy and safety data from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials WES...

2023-11-15 13:26:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most exciting opportunities can be found in biotech stocks . In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money. Look a...

2023-11-13 07:47:46 ET Summary Arcutis faces competition from Otezla and Vtama in the treatment of plaque psoriasis. Topical therapies for psoriasis have limitations and biologics are expensive, limiting their use. Zoryve, Arcutis' approved drug, has seen positive prescription...

2023-11-08 13:31:15 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Mizuho cuts Articus to neutral, cites lower-than-expected prescri...

2023-11-03 14:55:06 ET Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Conference Call November 03, 2023, 08:30 AM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards - Chief...

2023-11-03 07:43:22 ET More on Arcutis Biotherapeutics Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions Arcutis announces pricing of $100 million public offering Seeking Alpha’s Quant Rating on Arcutis Biotherapeutics For further...

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, ...

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...